Literature DB >> 16249953

An overview of drug development with special emphasis on the role of visual electrophysiological testing.

Mitchell Brigell1, Cun-Jian Dong, Serge Rosolen, Radouil Tzekov.   

Abstract

Visual electrophysiological techniques, such as electroretinography (ERG) and visual evoked potentials (VEP) can provide useful information on the safety, efficacy, and proper dosing of chemical entities under development as new drug therapies. During post-marketing safety surveillance, a variety of visual electrophysiological measures can be used to objectively assess and document individual patient response to ophthalmic drugs and ocular or visual system side effects of non-ophthalmic drugs. In this paper, the discovery, exploratory development, full-development and post-marketing stages of drug development are briefly outlined. The potential role of visual electrophysiological techniques in each of these stages is described and discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16249953     DOI: 10.1007/s10633-005-7338-9

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  79 in total

1.  Correlation of pattern electroretinogram with optic disc cup shape in ocular hypertension.

Authors:  T Salgarello; A Colotto; B Falsini; L Buzzonetti; L Cesari; G Iarossi; L Scullica
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-08       Impact factor: 4.799

2.  Selective excitotoxic degeneration of adult pig retinal ganglion cells in vitro.

Authors:  X Luo; V Heidinger; S Picaud; G Lambrou; H Dreyfus; J Sahel; D Hicks
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-04       Impact factor: 4.799

3.  The influence of MgCl2 and APB on the light-induced potassium changes and the ERG b-wave of the isolated superfused rat retina.

Authors:  R Hanitzsch; T Lichtenberger; W U Mattig
Journal:  Vision Res       Date:  1996-02       Impact factor: 1.886

4.  The photopic negative response of the flash electroretinogram in primary open angle glaucoma.

Authors:  S Viswanathan; L J Frishman; J G Robson; J W Walters
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-02       Impact factor: 4.799

5.  Calcium channel blocker D-cis-diltiazem does not slow retinal degeneration in the PDE6B mutant rcd1 canine model of retinitis pigmentosa.

Authors:  S E Pearce-Kelling; T S Aleman; A Nickle; A M Laties; G D Aguirre; S G Jacobson; G M Acland
Journal:  Mol Vis       Date:  2001-02-25       Impact factor: 2.367

6.  Signal transmission along retinal rods and the origin of the electroretinographic a-wave.

Authors:  R D Penn; W A Hagins
Journal:  Nature       Date:  1969-07-12       Impact factor: 49.962

7.  Narrow-band filtering for monitoring low-amplitude cone electroretinograms in retinitis pigmentosa.

Authors:  S O Andréasson; M A Sandberg; E L Berson
Journal:  Am J Ophthalmol       Date:  1988-05-15       Impact factor: 5.258

8.  Electroretinographic findings in iris neovascularization due to acute central retinal vein occlusion.

Authors:  M A Johnson; T J McPhee
Journal:  Arch Ophthalmol       Date:  1993-06

9.  Abnormal activation and inactivation mechanisms of rod transduction in patients with autosomal dominant retinitis pigmentosa and the pro-23-his mutation.

Authors:  D G Birch; D C Hood; S Nusinowitz; D R Pepperberg
Journal:  Invest Ophthalmol Vis Sci       Date:  1995-07       Impact factor: 4.799

10.  Visual evoked potentials to multiple temporal frequencies. Use in the differential diagnosis of optic neuropathy.

Authors:  P Bobak; R Friedman; M Brigell; J Goodwin; R Anderson
Journal:  Arch Ophthalmol       Date:  1988-07
View more
  2 in total

1.  Effects of hypercapnia on the electroretinogram in sevoflurane and isoflurane anaesthetized dogs.

Authors:  O Varela Lopez; J C Alvarez Vazquez; A Gonzalez Cantalapiedra; S G Rosolen
Journal:  Doc Ophthalmol       Date:  2010-02-10       Impact factor: 2.379

Review 2.  Visual Electrodiagnostic Testing in Birdshot Chorioretinopathy.

Authors:  Radouil Tzekov; Brian Madow
Journal:  J Ophthalmol       Date:  2015-07-13       Impact factor: 1.909

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.